Get started
Author

Ana Martinez–Naharro

Observed names: A Martinez-Naharro, Ana Martinez, Ana Martinez - Naharro, Ana Martinez De Azcona Naharro, Ana Martinez Naharro, Ana Martinez – Naharro, Ana Martinez-Naharro, Ana Martinez-Naharrro, Ana Martinez-naharro, Ana Martinez‐Naharro, Ana Martínez Naharro, Ana Martínez-Naharro, Martinez de Azcona Naharro, Ana, Martinez-Naharro A, Martinez-Naharro, A, Martinez-Naharro, Ana
Observed institutions: Brigham and Women's Hospital, University College Hospital, Harvard University, Royal Free London NHS Foundation Trust, The Royal Free Hospital, Royal Brompton Hospital, NIHR Royal Brompton Cardiovascular Biomedical Research Unit, BridgeBio (United States), Hospital Universitario Infanta Cristina, University College London, Imperial College London
ORCID: 0000-0003-3595-6988
Observed ORCID: 0000-0003-3595-6988
OpenAlex ID: A5090961709
A new staging system for cardiac transthyretin amyloidosis
2017 · Julian D Gillmore, Thibaud Damy, et al. · European Heart Journal · 778
Natural History, Quality of Life, and Outcome in Cardiac Transthyretin Amyloidosis
2019 · Thirusha Lane, Marianna Fontana, et al. · Circulation · 537
PDF
Magnetic Resonance in Transthyretin Cardiac Amyloidosis
2017 · Ana Martinez-Naharro, Thomas A. Treibel, et al. · Journal of the American College of Cardiology · 438
PDF
Native T1 and Extracellular Volume in Transthyretin Amyloidosis
2018 · Ana Martinez-Naharro, Tushar Kotecha, et al. · JACC. Cardiovascular imaging · 295
PDF
Multiparametric Echocardiography Scores for the Diagnosis of Cardiac Amyloidosis
2019 · Michele Boldrini, Francesco Cappelli, et al. · JACC. Cardiovascular imaging · 269
PDF
Automated Pixel-Wise Quantitative Myocardial Perfusion Mapping by CMR to Detect Obstructive Coronary Artery Disease and Coronary Microvascular Dysfunction
2019 · Tushar Kotecha, Ana Martinez-Naharro, et al. · JACC. Cardiovascular imaging · 265
PDF
Cardiac amyloidosis
2018 · Ana Martinez-Naharro, Philip N Hawkins, et al. · Clinical Medicine · 259
Impact of Earlier Diagnosis in Cardiac ATTR Amyloidosis Over the Course of 20 Years
2022 · Adam Ioannou, Rishi K. Patel, et al. · Circulation · 247
PDF
Myocardial Edema and Prognosis in Amyloidosis
2018 · Tushar Kotecha, Ana Martinez-Naharro, et al. · Journal of the American College of Cardiology · 234
PDF
Abnormal Lung Function in Adults With Congenital Heart Disease: Prevalence, Relation to Cardiac Anatomy, and Association With Survival
2013 · Rafael Alonso-Gonzalez, Francesco Borgia, et al. · Circulation · 218
PDF
Reduction in CMR Derived Extracellular Volume With Patisiran Indicates Cardiac Amyloid Regression
2020 · Marianna Fontana, Ana Martinez-Naharro, et al. · JACC. Cardiovascular imaging · 200
PDF
Noncontrast Magnetic Resonance for the Diagnosis of Cardiac Amyloidosis
2019 · Andrea Baggiano, Michele Boldrini, et al. · JACC. Cardiovascular imaging · 195
Cardiac Structural and Functional Consequences of Amyloid Deposition by Cardiac Magnetic Resonance and Echocardiography and Their Prognostic Roles
2018 · Daniel S. Knight, Giulia Zumbo, et al. · JACC. Cardiovascular imaging · 192
Prognostic utility of the Perugini grading of 99mTc-DPD scintigraphy in transthyretin (ATTR) amyloidosis and its relationship with skeletal muscle and soft tissue amyloid
2016 · David F Hutt, Marianna Fontana, et al. · European Heart Journal - Cardiovascular Imaging · 190
Echocardiographic phenotype and prognosis in transthyretin cardiac amyloidosis
2019 · Liza Chacko, Raffaele Martone, et al. · European Heart Journal · 182
PDF
Diagnostic imaging of cardiac amyloidosis
2020 · Ana Martinez-Naharro, A. John Baksi, et al. · Nature Reviews Cardiology · 171
Clinical Importance of Left Atrial Infiltration in Cardiac Transthyretin Amyloidosis
2021 · Francesco Bandera, Raffaele Martone, et al. · JACC. Cardiovascular imaging · 168
Conventional heart failure therapy in cardiac ATTR amyloidosis
2023 · Adam Ioannou, Paolo Massa, et al. · European Heart Journal · 160
PDF
Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study
2020 · David Adams, Michael Polydefkis, et al. · The Lancet Neurology · 159
CMR-Verified Regression of Cardiac AL Amyloid After Chemotherapy
2017 · Ana Martinez-Naharro, Amna Abdel-Gadir, et al. · JACC. Cardiovascular imaging · 134
PDF
High Prevalence of Intracardiac Thrombi in Cardiac Amyloidosis
2019 · Ana Martinez-Naharro, Esther Gonzalez-Lopez, et al. · Journal of the American College of Cardiology · 120
PDF
Cardiovascular magnetic resonance in light-chain amyloidosis to guide treatment
2022 · Ana Martinez-Naharro, Rishi Patel, et al. · European Heart Journal · 118
PDF
Longitudinal strain is an independent predictor of survival and response to therapy in patients with systemic AL amyloidosis
2021 · Oliver C Cohen, Andreia Ismael, et al. · European Heart Journal · 113
Prevalence, Characteristics and Outcomes of Older Patients with Hereditary Versus Wild-Type Transthyretin Amyloid Cardiomyopathy
2023 · Aldostefano Porcari, Yousuf Razvi, et al. · European Journal of Heart Failure · 103
PDF
Tc-99m labelled bone scintigraphy in suspected cardiac amyloidosis
2023 · Muhammad Umaid Rauf, Philip N Hawkins, et al. · European Heart Journal · 99
PDF
Works count: 209
Citation count: 8,335
H-index: 45
I10-index: 85
Year
Topic
Type